Bionomics IPO Presentation Deck

Kv3.1 / Kv3.2 Ion Channel Activators for Cognitive Dysfunction and Negative Symptoms Promising therapeutic strategy for improving cognitive disfunction and social withdrawal symptoms -600 COMPOUNDS SYNTHESIZED 2 SERIES PATENTED Lead Compound BL-76 Bionomics Back-up Compounds 2 Patents Published Bionomics' molecules target Kv3.1/3.2 ion channels on parvalbumin positive, gabaergic interneurons in the pre-frontal cortex *Coswwwodas Potential in schizophrenia, Autism Spectrum disorders and conditions with cognitive impairments 40 Lead Compound BL-76 Fully Reverses PCP-induced Cognitive Deficit in Mice in the T-maze 100% -0%--75% - 43% -70%- 103% REVERSAL OF PCP EFFECTS Vehicle PCP 3 mg/kg 0 Risperidona 0.001 mg/kg (p IP CP BL-T6 jn glkg polPCP BL-76 10mg/kg po IP CP BL-78 30mg/kg po/PCP 27

View entire presentation